Obesity as a risk factor for severe COVID-19 and complications

Demeulemeester F.^{1*}, De Punder K.¹, van Heijningen M.¹, van Doesburg F.¹

¹Natura Foundation, Numansdorp, The Netherlands

* Correspondence: f.demeulemeester@naturafoundation.com

Keywords: Coagulopathy, COVID-19, Cytokine storm, Inflammation, Leptin, Obesity, SARS-CoV-2

Abstract

Emerging data suggest that obesity is a major risk factor for the progression of major complications such as, acute respiratory distress syndrome (ARDS), cytokine storm and coagulopathy in COVID-19. Understanding the mechanisms underlying the link between obesity and disease severity as a result of SARS-CoV-2 infection is crucial for the development of new therapeutic interventions and preventive measures in this high-risk group. We propose that multiple features of obesity contribute to the prevalence of severe COVID-19 and complications. First, viral entry can be facilitated by the upregulation of viral entry receptors, like angiotensin-converting enzyme 2 (ACE2), among others. Second, obesity-induced chronic inflammation and disruptions of leptin signaling can result in a disproportionate or hyper-inflammatory response, which together with elevated ferritin levels can be a direct cause for complications, such as ARDS and cytokine storm. Third, the negative consequences of obesity on blood coagulation can contribute to the progression of thrombus formation and hemorrhage. In this review we summarize clinical findings that provide insight into the relationship between obesity and COVID-19 disease severity and discusses potential mechanisms that could convey the risk for major complications in patients suffering from obesity.

1 Introduction

The novel coronavirus SAR-CoV-2 that first appeared in the Chinese city of Wuhan is still causing a global pandemic with a death toll that already exceeds 1,330,000 people and continues to grow every day (number from John Hopkins University).

SARS-CoV-2 is the virus that causes COVID-19, a clinical picture characterized by fever, coughing, muscle pain and fatigue and can evolve into hyperinflammation, cytokine storm, ARDS and COVID-associated-coagulopathy (CAC) [1,2]. A large number of patients severely ill with COVID-19 arriving in the ICU are overweight or suffer from obesity [3]. These conditions, as well as smoking, age, type II diabetes and cardiovascular diseases, appear to be major risk factors for serious complications and increased mortality in COVID-19 [4–6].

In order to facilitate a better understanding of the mechanistic pathways linking obesity with COVID-19 symptom severity, we summarize clinical findings that provide insight into the relationship between obesity and COVID-19 disease severity. Next, we discuss possible mechanisms underlying the link between obesity and major disease complications as a result of SARS-CoV-2 infection, which is of key importance for the development of therapeutic interventions, as well as for developing preventative strategies in this high-risk group.

2 Obesity

2.1 Obesity is a common disease associated with chronic inflammation and leptin resistance

The prevalence of obesity has increased worldwide over the last 50 years. In 2015 the mean prevalence of obesity in adults of selected countries was 19.5% and ranged from 3.7% in Japan to 38.2% in the United States [7]. Obesity ($\text{BMI} \geq 30 \text{ kg/m}^2$) is a major risk factor for the development of non-communicable diseases and is defined by the WHO as abnormal or excessive fat accumulation that might impair health [8].

Fat or adipose tissue, originally regarded as a simple organ for storing energy, is currently viewed as one of the most important endocrine organs [9–11]. Fat cells, or adipocytes, produce cytokine-like hormones, called adipokines, which play a major role in metabolism and inflammation [11]. Adipocytes in different regions fulfill different functions. Distinctions should be made between brown and white adipocytes, between ectopic and non-ectopic and between visceral and subcutaneous adipose tissue to accurately estimate the impact of the adipose tissue on the patient's health. For example, visceral fat, but not so much subcutaneous fat accumulation, promotes systemic inflammation and is associated with impairments of glucose and lipid metabolism [12,13].

Obesity is associated with chronic inflammation, resulting from immune cell activity in dysfunctional adipose tissue. In obesity, the excessive presence and hypertrophy of adipocytes result in hypoxia, cell stress and apoptosis. The hypoxic environment induces the infiltration of immune cells into the adipose tissue as a result of the expression of chemo attractive molecules [14]. Also, hypertrophic adipocytes produce multiple pro-inflammatory adipokines [15].

Leptin is one of the multiple adipokines produced by adipocytes and informs the brain about the energy status of the body [16]. The percentage of total body fat is the most important determinant of leptin levels [17]. Given their high percentage of total body fat, individuals suffering from obesity produce more leptin than lean persons. Therefore, they ultimately develop hyperleptinemia, often accompanied with central leptin resistance, due to which their appetite and satiety regulation is disrupted [18]. In addition to the regulation of hunger and satiety, leptin also has pro-inflammatory functions [19], further contributing to a chronic inflammatory state in individuals suffering from obesity [20].

2.2 Obesity and COVID-19 disease severity

In the following section, we summarize clinical findings supporting an association between obesity and COVID-19 disease severity (see also Table 1). Most studies investigating this association used BMI categories as the predictor variable [21–25]. Outcome variables included: hospitalization [26,27], ICU admission [28,29], intubation [21,22], invasive mechanical ventilation [23,29,30], disease severity [24,25] and death. Of the five studies investigating the association between BMI and mortality in hospitalized COVID-19 patients, four studies observed an increased mortality rate in patients that were overweight ($\text{BMI } 25\text{--}29.99$) [21], or suffering from obesity ($\text{BMI} \geq 30$) [22] or severe obesity ($\text{BMI} \geq 35$) [23,24]. One study observed no difference in in-hospital deaths between normal and overweight ($\text{BMI} > 28$) patients, but overweight patients did show more severe disease symptoms [25]. Because BMI does not discriminate between fat and lean body mass and poorly reflects fat distribution, two studies used measures of visceral adipose tissue (VAT) obtained by high-resolution computed tomography [26,28]. In COVID-19 patients reporting at the emergency department, subsequent admission to the ICU was associated with 30% higher VAT and 30% lower subcutaneous adipose tissue (SAT) [28]. Another study observed no differences in BMI but did see

higher VAT and a higher VAT/total adipose tissue ratio in hospitalized patients compared to outpatients that did not require hospitalization [26]. To summarize, numerous studies indicate that obesity is associated with increased disease severity and mortality in COVID-19.

3 Underlying mechanisms linking obesity to major complications as a result of SARS-CoV-2 infection

To gain a better understanding of the pathophysiology of COVID-19 in patients suffering from obesity, in the next section we provide an overview of the mechanistic pathways linking obesity with COVID-19 disease severity.

3.1 Obesity facilitates viral entry of SARS-CoV-2

Cell entry of SARS-CoV-2 virus depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Obesity can promote viral entry by the upregulation of some of these host cell receptors.

3.1.1 Obesity increases ACE2 expression

Viral entry into target cells is facilitated by binding of the SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme (ACE)-2 and the priming of the S protein by serine protease TMPRSS2 and the endosomal cysteine proteases cathepsin B and L expressed by host cells [31,32]. ACE2 is part of the renin-angiotensin system (RAS) and plays an important role in regulating systemic blood pressure. Renin induces proteolytic cleavage of angiotensinogen into angiotensin (Ang)-I, which is then converted into Ang-II by ACE1. The action of ACE1 induces vasoconstriction and inflammation while ACE2 acts as a counter-regulator of the RAS. ACE2 induces vasodilatation and has an anti-inflammatory effect, by converting the pro-inflammatory Ang-II into Ang-1-7 which opposes the actions of Ang-II. ACE2 is expressed in a wide variety of human tissues such as the small intestine, testis, kidneys, heart, thyroid, lungs and brain [33]. Adipose tissue also expresses ACE2, together with all other components of the RAS. The RAS has been shown to play an important role in lipid metabolism and vice versa [34–37]. By analyzing available transcriptome data of a mouse model of obesity, it was shown that diet-induced obese mice also displayed increased expression of ACE2 in the lung epithelium [38]. The expression of ACE2 was correlated with the expression of genes that code for sterol response element binding proteins 1 and 2, transcription factors controlling lipid synthesis and adipogenesis [38].

In addition, a number of studies indicate that ACE2 expression can be upregulated by a wide range of pro-inflammatory cytokines [39,40]. The chronic inflammatory state that characterizes obesity could therefore potentially facilitate viral entry [39].

Patients suffering from obesity have more adipose tissue and consequently an increased number of ACE2-expressing cells and a larger amount of ACE2 proteins. It has been suggested that viral pools can lodge in adipose tissue and promote shedding, immune activation, and chronic excessive cytokine release [41]. Earlier studies could show that other viruses such as influenza A, HIV and cytomegalovirus use the adipose tissue as a reservoir [42].

In conclusion, obesity and its related pro-inflammatory state can promote viral entry, viral shedding and excessive immune activation through the upregulation of ACE2.

3.1.2 Activation of the unfolded protein response by GRP78

Another receptor that provides viral entry for SARS-CoV-2 is glucose-regulated protein 78 (GRP78) [43]. GRP78, also called immunoglobulin heavy chain binding protein (BiP), is part of the heat shock protein 70 family and is a molecular chaperone found in the lumen of the endoplasmic reticulum (ER). GRP78 functions as an anti-apoptotic regulator that protects cells against cell death induced by ER stress [44]. GRP78 does this by ensuring the correct folding and assembly of proteins in the ER and by initiating the degradation of misfolded proteins. This evolutionarily preserved cellular homeostatic response to ER stress, also named the ER-stress or unfolded protein response (UPR) [45] can be disrupted by viruses in the establishment of acute, chronic and latent infections [46] .

Normally, new foreign viral proteins produced inside host cells would be immediately degraded by the UPR. Therefore, viruses that acquired the ability to disrupt the process designed to degrade unrecognized protein have a clear advantage. Binding GRP78 is a mechanism commonly used by viruses like the Ebola virus, Zika virus, Dengue virus, Japanese encephalitis virus, Coxsackie A9, MERS-CoV and the Borna disease virus to ensure safe entry into host cells and to facilitate viral replication. [47–53]. Also, the S proteins of the SARS-CoV-2 virus bind GRP78 with high affinity [43].

Various factors associated with obesity induce ER stress and consequently UPR activation. These factors, including hypoxia, reactive oxygen species, insulin resistance, nutritional imbalance and excessive fat storage [54–56], stimulate GRP78 expression as a mechanism of the UPR to restore normal cell functions [57,58]. For example, evidence from *in vitro* and *in vivo* studies shows that dyslipidemia is associated with GRP78 overexpression in adipocytes (especially in white adipose tissue) [59], pneumocytes [60], neurons of the hypothalamus [61] and hepatocytes [62]. GRP78 overexpression induces its translocation to the cell membrane or cell surface. When GRP78 is located on the cell surface, it is referred to as cell surface GRP78 (cs-GRP78). This acts as a multi-functional receptor that can bind various ligands and plays a crucial role in apoptosis and inflammation, among other things [44]. By binding to cs-GRP78, SARS-CoV-2 could ensure safe entry into host cells [43].

3.1.3 Heparan sulfate proteoglycans and neuropilin-1

Heparan sulfate proteoglycans (HSPGs) are located in the extracellular matrix and at the surface of the cell, where they act as co-receptors for various ligands. HSPGs are widely expressed and mediate many biological activities, including angiogenesis, blood coagulation, developmental processes, and cell homeostasis. The binding of cytokines, chemokines and growth factors to HSPGs at the cell surface prevents their degradation [63].

Syndecans are a group of transmembrane HSPGs that have been shown to facilitate the cellular entry of SARS-CoV-2 *in vitro*. Among syndecans, syndecan-4 was most efficient in mediating SARS-CoV-2 uptake, yet overexpression of other isoforms, including syndecan-1 and the neuronal syndecan-3, also increased SARS-CoV-2 internalization [64,65]. Syndecans 1 and 4 are widely expressed in most adult tissues [66] and, among other functions, are involved in lipid metabolism, by clearing pro-atherogenic remnant lipoproteins from the circulation [67]. In addition, syndecan-4 is crucial for adipocyte differentiation and proliferation [68].

Neuropilin-1 (NRP-1), a membrane-bound co-receptor for growth factors such as vascular endothelial growth factor (VEGF), also facilitates viral entry of SARS-CoV-2 *in vitro* [69]. NRP-1 is strongly involved in adipogenesis and is highly upregulated during adipose-derived stem cell differentiation [70].

In obesity, both higher circulating pro-atherogenic lipoprotein levels [71] and the constant expansion of adipose tissue accompanied by the differentiation and proliferation of adipose-derived stem cells, could increase syndecans and NRP-1 expression in various tissues. For example, conditions associated with obesity, such as non-alcoholic fatty liver disease and cardiovascular diseases, have been associated with increased circulating syndecan-1 concentrations and higher syndecan-1 expression in various cell types [72]. The up-regulation of syndecans and NRP-1 could facilitate cellular entry of SARS-CoV-2. However, further studies need to confirm this theory.

3.2 Disrupted leptin signaling in obesity can induce a hyperinflammation during SARS-CoV-2 infection

3.2.1 Leptin is an important regulator of energy metabolism

Leptin is a pleiotropic protein secreted primarily from white adipose tissue into the bloodstream and can be transported across the blood-brain barrier. Through its effects on the central nervous system and peripheral tissues, leptin is an important regulator of energy homeostasis, metabolism, neuroendocrine and immune system function [73].

Obesity proceeds from a chronic energy imbalance and is characterized by persistent hyperleptinemia and central leptin resistance. Under physiological conditions, leptin informs the brain about the energy status in the periphery, but in obesity, signaling to regulatory centers in the brain that normally inhibit food intake and regulate body weight and energy homeostasis is disrupted. Mechanisms underlying leptin resistance, include disruption of leptin signaling in hypothalamic and other CNS neurons, impaired leptin transport across blood-brain barrier, hypothalamic inflammation, endoplasmic reticulum stress, and autophagy [73,74].

3.2.2 Leptin modulates the immune system

Leptin signaling results in the modulation of the innate and adaptive immune system on multiple levels. Leptin signaling occurs primarily through binding leptin to the long isoform of the leptin receptor, followed by activation of the JAK/STAT pathway [2]. Increased leptin production stimulates chemotaxis and neutrophil survival, induces pro-inflammatory cytokine production, chemotaxis [75,76], and higher expression of adhesion molecules by eosinophils and basophils [77,78]. Monocyte activation and proliferation as well as the production of pro-inflammatory cytokines and chemotaxis are also stimulated by leptin [19]. Certain immune cells, more specifically those that contain the long isoform of the leptin receptor, may become unresponsive to leptin, or leptin resistant, when exposed to high leptin levels for an extended period of time [79,80]. Therefore, chronic hyperleptinemia, as seen in obesity, can have detrimental effects on the immune response [18]. For example, under physiological conditions, short-term elevated leptin levels cause an increase and higher cytotoxicity of NK cells [81]. However, in obesity, chronic hyperleptinemia can produce dysfunctional NK cells [79].

Also, the adaptive immune system responds to leptin. Leptin induces a shift towards the more pro-inflammatory Th1 response [18], activates T and B lymphocytes, and inhibits regulatory T cells [81,82]. Regulatory T cells are involved in suppressing an excessive immune response [83,84]. It was demonstrated in patients suffering from obesity that leptin levels and BMI were inversely correlated with the number of regulatory T cells [85].

In obesity, leptin levels can be further increased due to acute inflammation, infection or sepsis [86]. Elevated leptin levels, in combination with the obesity-induced pro-inflammatory state, further increases the risk for the development of a disproportionate or hyper-inflammatory response induced

by SARS-CoV-2 infection. Furthermore, SARS-CoV-2 infection increased the expression of the gene that encodes for suppressor of cytokine signaling 3 (SOCS3) in lung epithelium [38]. This gene is a key regulator of inflammation and an inhibitor of leptin signaling. Increased SOCS3 expression as a result of SARS-CoV-2 infection could therefore further impair leptin signaling and negatively influence the immune response in patients suffering from obesity [87].

3.3 Hyperferritinemia as a result of hyperinflammation can induce a cytokine storm

Ferritin is an iron-binding molecule that stores iron in a biologically available form for vital cellular processes and protects proteins, lipids and DNA from the potential toxicity of this metal element. Ferritin is a marker of the acute phase response, and its secretion is regulated by pro-inflammatory cytokines. However, the origin of circulating serum ferritin during inflammatory conditions is still debated [88]. While some describe serum ferritin as a leakage product of damaged cells [89], increasing evidence shows that circulating serum ferritin levels may play a critical role in the inflammatory process [91]. Serum ferritin may protect the host during active infection by limiting the availability of iron to pathogens, a phenomenon called ‘nutritional immunity’ [90–92].

Also, COVID-19 is accompanied by a rise in circulating ferritin levels. Serum ferritin levels can be used as a diagnostic marker and even a predictor of COVID-19 severity [93–95]. The elevated ferritin levels observed in COVID-19 patients are probably a consequence of the inflammatory process induced by SARS-CoV-2 infection. Alternatively, it has been suggested that ferritin levels increase due to the break-down of red blood cells by the SARS-CoV-2 virus. By breaking down red blood cells and then attacking the hemoglobin 1-beta chain, the virus can separate iron from the porphyrin ring to eventually hijack the porphyrin ring, producing a rise in free iron and subsequently increasing ferritin levels [96]. Although hemoglobin-related biomarkers such as serum ferritin, progressively increase as the severity of COVID-19 increases [97–99], there is very limited evidence supporting this hypothesis [96].

Several studies have shown a relationship between obesity and elevated ferritin serum levels [100]. The chronic inflammatory state as a result of the increased release of pro-inflammatory cytokines by adipocytes and a pro-inflammatory oriented immune system due to hyperleptinemia [11,18,20,86], likely contribute to the manifestation of elevated ferritin levels in individuals with obesity.

Infection with SARS-CoV-2 in individuals with obesity as pre-existing condition can progress into a hyperferritinaemic state as both SARS-CoV-2 and obesity initiate the release of serum ferritin. Ferritin further stimulates macrophages to produce pro-inflammatory cytokines, mainly IL-1, IL-6 and IL-17. At overly elevated serum ferritin levels, macrophages produce so many cytokines that the situation can evolve into a cytokine storm [88]. The cytokine storm occurring with COVID-19 could be considered a hyperferritinemia syndrome [101] and is a significant adverse development in the course of the disease, translating into a marked increased risk of death [102].

4 Multiple risk factors for developing coagulopathy in obese COVID-19 patients

About a third of ICU patients with COVID-19 develop thrombotic complications [103,104]. The characteristics of CAC seems to be more complex than the development of thromboinflammation triggered by systemic inflammation in response to infection [105]. For example, the presence of systemic microthrombi and hemorrhage in SARS-CoV-2 affected organs indicates a malfunction in the coordination of coagulation and fibrinolysis [106]. Moreover, CAC is commonly associated with increased D-dimer and fibrinogen levels, indicating there is initially no suppression of fibrinolysis

[107]. Abnormalities in other coagulation biomarker such as prothrombin time and platelet count are less frequent and seem less affected by SARS-CoV-2 infection [108].

In the following section we provide an overview of parameters that are dysregulated in obesity and could contribute to increase the risk of developing CAC.

4.1 Hyperleptinemia

Hyperleptinemia is a risk factor for developing thrombi. Leptin affects blood clotting by enhancing prothrombotic and antifibrinolytic protein expression in vascular and inflammatory cells and thereby producing a more hypofibrinolytic state [109]. A large population-based cohort study from The Netherlands, examining associations between serum leptin concentrations and coagulation factor concentrations and parameters of platelet activation showed that serum leptin concentrations were positively associated with concentrations of coagulation factor VIII and IX [110]. Hyperleptinemia and leptin resistance have also been described as risk factors for the development of cardiovascular diseases [111,112]. As elevated leptin levels are a key feature of obesity [111,113,114], the prothrombotic state produced by hyperleptinemia, increases the risk for developing thrombotic complications in COVID-19.

4.2 PAI-1 production by adipocytes

Plasminogen activator inhibitor 1 (PAI-1) is the primary physiological inhibitor of plasminogen activation. Elevations in plasma PAI-1 compromise normal fibrin clearance mechanisms and promote thrombosis. PAI-1 is also produced by adipocytes and its production is dramatically upregulated in obesity [115,116]. PAI-1 mRNA expression was demonstrated in the visceral and subcutaneous fat of obese rats [117] and in adipose tissue from human subjects [118]. In both rats and humans, VAT produced significantly more PAI-1 compared to SAT. These results are consistent with the observation that cardiovascular risk is most closely correlated with central obesity [119]. PAI-1 produced by adipocytes and vascular endothelium is involved in tissue expansion and angiogenesis necessary during adipose tissue development [120].

Several molecular mechanisms are involved in the upregulation of PAI-1 mRNA expression in obesity. For example, different cytokines including TNF- α and TGF- β , triglycerides, free fatty acids and insulin all stimulate PAI-1 expression in adipose tissue [115]. Leptin, additionally, contributes to a prothrombotic state by increasing the expression of PAI-1 in vascular endothelium [121]. Thus, obesity-induced upregulation of PAI-1 further increases the risk for coagulopathy, following SARS-CoV-2 infection.

4.3 Endothelial dysfunction

The endothelium serves as a dynamic barrier that separates blood from interstitia. Endothelial cells respond rapidly to changes in the circulation and become activated according to environmental needs [122]. The multitude of physiological functions of the endothelium are still a topic of extended research. Endothelium is recently described as an active regulator of lipid and glucose homeostasis [123].

Endothelial cells play a major role in vascular homeostasis and blood coagulation. Endothelial dysfunction is considered a hallmark of metabolic diseases and is characterized by a loss of molecular cell functions and inevitably causing coagulopathy. Endothelial dysfunction contributes to various pathological states such as atherothrombosis, arterial thrombosis (stroke, visceral and

peripheral artery occlusive diseases), venous thrombosis, intravascular coagulation and thrombotic microangiopathies [122].

Oxidative stress is considered the major cause of endothelial dysfunction. Obesity generates oxidative stress through different pathways, such as hyperglycemia, known to trigger vascular damage by inducing the accumulation of reactive oxygen species (ROS) [124]. Hyperglycemia also activates nuclear factor- κ B, a transcription factor that mediates vascular inflammation [124]. The exacerbated production of pro-inflammatory cytokines by adipose tissue further increases oxidative stress levels and promotes the upregulation of procoagulant factors and adhesion molecules in the endothelium, the downregulation of anticoagulant regulatory proteins, increases thrombin generation, and enhances platelet activation [125]. Not coincidentally, endothelial dysfunction is a common feature of comorbidities that increase the risk for severe COVID-19, including hypertension, obesity, diabetes mellitus, coronary artery disease and heart failure.

Furthermore, because, ACE2 is expressed abundantly on vascular endothelial cells of both small and large arteries and veins [126], SARS-CoV-2 infection of endothelial cells can further aggravate endothelial dysfunction. Endothelial damage and dysfunction may thus be the result of cellular infection by SARS-CoV-2, as well as a consequence of obesity-associated excessive systemic inflammation [127]. Evidently, patients with preexisting endothelial dysfunction are more vulnerable to develop severe complications, including coagulopathy, following SARS-CoV-2 infection.

4.4 Vitamin K

Vitamin K is a fat-soluble vitamin, required for the carboxylation of vitamin K-dependent proteins (VKDP). Intrahepatic VKDP include coagulation factors II, VII, IX, X, and different anticoagulant proteins. Extra-hepatic VKDP include diverse gammacarboxyglutamate (Gla) proteins involved in maintaining bone homeostasis, as well as inhibiting ectopic calcification [128]. Vitamin K is not a single entity but a family of structurally related molecules such as phyloquinone, also referred to as vitamin K1, and menaquinone or vitamin K2. K1 deficiency gives rise to hemorrhagic disorders while K2 deficiency leads to vascular calcifications and atherosclerosis [129–131].

Obesity is linked with vitamin K1 [132] and K2 deficiency [133]. For example, lower vitamin K1 status was observed in patients with obesity compared to healthy individuals [132]. Yet, differences in dietary K1 intake could not fully explain this observation. It has been suggested that vitamin K1 accumulates in adipocyte tissue, thereby reducing the bioavailability of this vitamin in individuals with obesity [132]. Similar mechanism has been established for other fat-soluble vitamins [134,135]. Vitamin K1 can be converted into menaquinone-4 (MK-4), an exceptional form of vitamin K2 with high bioavailability [136,137]. Because MK-4 is limitedly present in the diet, MK-4 deficiency is common, especially among persons suffering from obesity [133].

The triage theory states that during poor dietary supply, vitamins are preferentially utilized for functions important for immediate survival. According to this theory it can be explained that real hemorrhagic disorders are rare even in a K1 deficient obese population; clotting factors essential for survival are preferably activated at the expense of vitamin K-dependent activation of Gla-proteins and K1 conversion to MK-4 [138].

Vitamin K status was assessed in COVID-19 patients by measuring uncarboxylated Gla matrix protein (ucMGP). This measure is commonly used to evaluate vitamin K status, since vitamin K deficiency results in elevated levels of circulating ucMGP. Levels of ucMGP were significantly elevated in COVID-19 patients compared to controls and were significantly higher in COVID-19

patients with unfavorable outcome compared to those with less severe disease [139]. Matrix Gla-protein protect against decalcification of vasculature and elastic fibers in the extracellular matrix of the lungs. In COVID-19, elastic fiber degradation combined with calcification of these fibers due to low K2 status could aggravate lung injury and lung fibrosis [139].

Thus, to summarize, we can argue that several factors associated with obesity increase the risk for CAC, including elevated leptin levels, increased PAI-1 levels, endothelial dysfunction and decreased bioavailability of vitamin K. The latter is possibly also involved in the development of more severe lung injury in COVID-19.

5 Conclusions and implications for further research

Obesity cannot simply be defined as an excess of fat cells. Adipose tissue releases many active substances, such as adipokines, cytokines and components of the RAS, all influencing the brain and metabolic and immune system. Individuals suffering from obesity have a tendency towards a more pro-inflammatory immune system. Also, certain immune cells, more specifically those that contain the long isoform of the leptin receptor, may become unresponsive to leptin, or leptin resistant, when exposed to high leptin levels for an extended period of time. Furthermore, obesity is associated with large, hypoxic adipocytes, resulting in increased cell stress, apoptosis and oxidative stress. The combination of chronic inflammation, hyperleptinemia with leptin resistance, and oxidative stress is the basis for many inflammatory diseases [18,81,111,114,140].

Being obese increases the risk of SARS-CoV-2 infection and complications via several mechanisms. First, viral entry is enhanced due to increased ACE2, csGRP78 and presumably HSPG and NRP-1 expression levels in various cell types, like pneumocytes and adipocytes. Second, the immune system is unable to provide an adequate immune response and could overreact as a result of pro-inflammatory 'priming' due to excessive fat tissue and ferritin levels, eventually triggering a cytokine storm [88,101]. Finally, hyperleptinemia, PAI-1 production by adipocytes and endothelial cells, endothelial dysfunction and low bioavailability of vitamin K, all increase the risk for the development of thrombus formation and hemorrhage.

An important lesson learned from the coronavirus pandemic is the importance of a healthy lifestyle to positively influence the course of COVID-19 disease. A non-processed nutrient-rich diet [141–143], limited excessive or overly energy-rich food, sufficient and intensive movement [144], sufficient sleep [145] and avoiding chronic psycho-emotional stress [146] are all efficient health-promoting measures in the prevention of chronic, non-communicable diseases associated with obesity [147]. We also advocate an integrated multidisciplinary approach in the fight against COVID-19. Future research must identify causes of severity and complications to develop efficient preventive measures and curative interventions.

6 Conflict of Interest

Natura Foundation is a trading name of Bonusan B.V.

7 Author Contributions

FdM developed the concepts, reviewed the literature and drafted the manuscript. MvH provided editorial assistance. KdP and FvD developed the concepts and provided final editorial oversight.

8 Funding

371 No funding

372 **9 Acknowledgments**

373 We are grateful for the input of all the members of the Natura Foundation research team including
374 Michaëla Van Langeveld, Margo Peinemann, Aldert Hoogland, Lotte Bos, Iris Brunsmann and
375 André Frankhuizen.

376 **10 References**

- 377 1. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation.
378 Blood. 2020 Jun 4;135(23):2033–40.
- 379 2. Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019
380 (COVID-19): A literature review. Journal of Infection and Public Health. 2020
381 May;13(5):667–73.
- 382 3. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization
383 Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus
384 Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly
385 Rep. 2020 Apr 17;69(15):458–64.
- 386 4. Engin AB, Engin ED, Engin A. Two important controversial risk factors in SARS-CoV-2
387 infection: Obesity and smoking. Environmental Toxicology and Pharmacology. 2020
388 Aug;78:103411.
- 389 5. Vardavas C, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob
390 Induc Dis [Internet]. 2020 Mar 20 [cited 2020 Jun 10];18(March). Available from:
391 [http://www.journalssystem.com/tid/COVID-19-and-smoking-A-systematic-review-of-the-](http://www.journalssystem.com/tid/COVID-19-and-smoking-A-systematic-review-of-the-evidence,119324,0,2.html)
392 [evidence,119324,0,2.html](http://www.journalssystem.com/tid/COVID-19-and-smoking-A-systematic-review-of-the-evidence,119324,0,2.html)
- 393 6. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its
394 effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.
395 International Journal of Infectious Diseases. 2020 May;94:91–5.
- 396 7. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019
397 May;15(5):288–98.
- 398 8. Obesity [Internet]. [cited 2020 Nov 26]. Available from:
399 <https://www.who.int/westernpacific/health-topics/obesity>
- 400 9. Chaldakov G, Stankulov I, Hristova M, Ghenev P. Adipobiology of Disease: Adipokines and
401 Adipokine-Targeted Pharmacology. CPD. 2003 May 1;9(12):1023–31.
- 402 10. Kershaw EE, Flier JS. Adipose Tissue as an Endocrine Organ. The Journal of Clinical
403 Endocrinology & Metabolism. 2004 Jun;89(6):2548–56.
- 404 11. Scherer PE. Adipose Tissue: From Lipid Storage Compartment to Endocrine Organ. Diabetes.
405 2006 Jun 1;55(6):1537–45.

- 406 12. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral Fat Adipokine Secretion Is
407 Associated With Systemic Inflammation in Obese Humans. *Diabetes*. 2007 Apr 1;56(4):1010–
408 3.
- 409 13. Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Kotani K, Tokunaga K. Pathophysiology
410 and Pathogenesis of Visceral Fat Obesity. *Obesity Research*. 1995 Sep;3(S2):187s–94s.
- 411 14. Vieira-Potter VJ. Inflammation and macrophage modulation in adipose tissues: Adipose tissue
412 macrophage modulation. *Cell Microbiol*. 2014 Oct;16(10):1484–92.
- 413 15. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and
414 immunity. *Nat Rev Immunol*. 2006 Oct;6(10):772–83.
- 415 16. Pandit R, Beerens S, Adan R a. H. Role of leptin in energy expenditure: the hypothalamic
416 perspective. *Am J Physiol Regul Integr Comp Physiol*. 2017 01;312(6):R938–47.
- 417 17. Wauters M, Mertens I, Considine R, De Leeuw I, Van Gaal L. Are leptin levels dependent on
418 body fat distribution in obese men and women? *Eat Weight Disord*. 1998 Sep 1;3(3):124–30.
- 419 18. Abella V, Scotece M, Conde J, Pino J, Gonzalez-Gay MA, Gómez-Reino JJ, et al. Leptin in
420 the interplay of inflammation, metabolism and immune system disorders. *Nat Rev Rheumatol*.
421 2017 Feb;13(2):100–9.
- 422 19. Conde J, Scotece M, Gómez R, Gómez-Reino JJ, Lago F, Gualillo O. At the crossroad
423 between immunity and metabolism: focus on leptin. *Expert Review of Clinical Immunology*.
424 2010 Sep;6(5):801–8.
- 425 20. Divella R, De Luca R, Abbate I, Naglieri E, Daniele A. Obesity and cancer: the role of adipose
426 tissue and adipo-cytokines-induced chronic inflammation. *J Cancer*. 2016;7(15):2346–59.
- 427 21. Nakeshbandi M, Maini R, Daniel P, Rosengarten S, Parmar P, Wilson C, et al. The impact of
428 obesity on COVID-19 complications: a retrospective cohort study. *Int J Obes (Lond)*.
429 2020;44(9):1832–7.
- 430 22. Frank RC, Mendez SR, Stevenson EK, Guseh JS, Chung M, Silverman MG. Obesity and the
431 Risk of Intubation or Death in Patients With Coronavirus Disease 2019. *Crit Care Med*.
432 2020;48(11):e1097–101.
- 433 23. Kim T, Roslin M, Wang JJ, Kane J, Hirsch JS, Ji Kim E, et al. Body Mass Index as a Risk
434 Factor for Clinical Outcomes in Patients Hospitalized with COVID-19 in New York. *Obesity*
435 (Silver Spring). 2020 Oct 31;
- 436 24. Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, et al. Severe
437 obesity, increasing age and male sex are independently associated with worse in-hospital
438 outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the
439 Bronx, New York. *Metabolism*. 2020;108:154262.
- 440 25. Rao X, Wu C, Wang S, Tong S, Wang G, Wu G, et al. The importance of overweight in
441 COVID-19: A retrospective analysis in a single center of Wuhan, China. *Medicine*
442 (Baltimore). 2020 Oct 23;99(43):e22766.

- 443 26. Chandarana H, Dane B, Mikheev A, Taffel MT, Feng Y, Rusinek H. Visceral adipose tissue in
444 patients with COVID-19: risk stratification for severity. *Abdom Radiol (NY)*. 2020 Aug 3;
- 445 27. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of obesity and its
446 genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort
447 data. *Metabolism*. 2020 Aug 22;112:154345.
- 448 28. Battisti S, Pedone C, Napoli N, Russo E, Agnoletti V, Nigra SG, et al. Computed Tomography
449 Highlights Increased Visceral Adiposity Associated With Critical Illness in COVID-19. *Dia*
450 *Care*. 2020 Oct;43(10):e129–30.
- 451 29. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al. Association
452 of Obesity with Disease Severity among Patients with COVID-19. *Obesity (Silver Spring)*
453 [Internet]. 2020 Apr 30 [cited 2020 Oct 29]; Available from:
454 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267224/>
- 455 30. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High Prevalence
456 of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring
457 Invasive Mechanical Ventilation. *Obesity (Silver Spring)*. 2020;28(7):1195–9.
- 458 31. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-
459 CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven
460 Protease Inhibitor. *Cell*. 2020 Apr 16;181(2):271-280.e8.
- 461 32. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-
462 CoV-2 by full-length human ACE2. *Science*. 2020 Mar 27;367(6485):1444–8.
- 463 33. Li M-Y, Li L, Zhang Y, Wang X-S. Expression of the SARS-CoV-2 cell receptor gene ACE2
464 in a wide variety of human tissues. *Infect Dis Poverty*. 2020 Apr 28;9(1):45.
- 465 34. Cassis LA. Fat cell metabolism: insulin, fatty acids, and renin. *Curr Hypertens Rep*. 2000
466 Apr;2(2):132–8.
- 467 35. Cassis LA, Police SB, Yiannikouris F, Thatcher SE. Local adipose tissue renin-angiotensin
468 system. *Current Science Inc*. 2008 Apr;10(2):93–8.
- 469 36. Massiéra F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc J-M, et al. Adipose
470 angiotensinogen is involved in adipose tissue growth and blood pressure regulation. *FASEB j*.
471 2001 Dec;15(14):1–25.
- 472 37. Yvan-Charvet L, Quignard-Boulangé A. Role of adipose tissue renin-angiotensin system in
473 metabolic and inflammatory diseases associated with obesity. *Kidney Int*. 2011 Jan;79(2):162–
474 8.
- 475 38. Heialy SA, Hachim M, Senok A, Tayoun AA, Hamoudi R, Alsheikh-Ali A, et al. Regulation
476 of angiotensin converting enzyme 2 (ACE2) in obesity: implications for COVID-19. 2020 Apr
477 18 [cited 2020 May 4]; Available from:
478 <http://biorxiv.org/lookup/doi/10.1101/2020.04.17.046938>

- 479 39. Hennighausen L, Lee HK. Activation of the SARS-CoV-2 receptor *Ace2* by cytokines through
480 pan JAK-STAT enhancers [Internet]. Genomics; 2020 May [cited 2020 Nov 4]. Available
481 from: <http://biorxiv.org/lookup/doi/10.1101/2020.05.11.089045>
- 482 40. Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. SARS-CoV-2
483 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is
484 detected in specific cell subsets across tissues. *Cell*. 2020 May;181(5):1016-1035.e19.
- 485 41. Ryan PM, Caplice NM. Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation,
486 and Cytokine Amplification in Coronavirus Disease 2019? *Obesity* (Silver Spring). 2020 May
487 31;28(7):1191–4.
- 488 42. Kassir R. Risk of COVID-19 for patients with obesity. *Obesity Reviews* [Internet]. 2020 Jun
489 [cited 2020 Nov 26];21(6). Available from:
490 <https://onlinelibrary.wiley.com/doi/abs/10.1111/obr.13034>
- 491 43. Ibrahim IM, Abdelmalek DH, Elshahat ME, Elfiky AA. COVID-19 spike-host cell receptor
492 GRP78 binding site prediction. *Journal of Infection*. 2020 May;80(5):554–62.
- 493 44. Ibrahim IM, Abdelmalek DH, Elfiky AA. GRP78: A cell's response to stress. *Life Sciences*.
494 2019 Jun;226:156–63.
- 495 45. Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein
496 response. *Nat Rev Mol Cell Biol* [Internet]. 2020 May 26 [cited 2020 Jun 11]; Available from:
497 <http://www.nature.com/articles/s41580-020-0250-z>
- 498 46. Chan S-W. The unfolded protein response in virus infections. *Front Microbiol* [Internet]. 2014
499 Sep 30 [cited 2020 Nov 23];5. Available from:
500 <http://journal.frontiersin.org/article/10.3389/fmicb.2014.00518/abstract>
- 501 47. Chu H, Chan C-M, Zhang X, Wang Y, Yuan S, Zhou J, et al. Middle East respiratory
502 syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto
503 host cells. *J Biol Chem*. 2018 Jul 27;293(30):11709–26.
- 504 48. Honda T, Horie M, Daito T, Ikuta K, Tomonaga K. Molecular Chaperone BiP Interacts with
505 Borna Disease Virus Glycoprotein at the Cell Surface. *JVI*. 2009 Dec 1;83(23):12622–5.
- 506 49. Mairiang D, Zhang H, Sodja A, Murali T, Suriyaphol P, Malasit P, et al. Identification of New
507 Protein Interactions between Dengue Fever Virus and Its Hosts, Human and Mosquito.
508 Dimopoulos G, editor. *PLoS ONE*. 2013 Jan 11;8(1):e53535.
- 509 50. Nain M, Mukherjee S, Karmakar SP, Paton AW, Paton JC, Abdin MZ, et al. GRP78 Is an
510 Important Host Factor for Japanese Encephalitis Virus Entry and Replication in Mammalian
511 Cells. Diamond MS, editor. *J Virol*. 2017 Mar 15;91(6):e02274-16, e02274-16.
- 512 51. Sager G, Gabaglio S, Sztul E, Belov G. Role of Host Cell Secretory Machinery in Zika Virus
513 Life Cycle. *Viruses*. 2018 Oct 15;10(10):559.

- 514 52. Triantafilou K, Fradelizi D, Wilson K, Triantafilou M. GRP78, a Coreceptor for
515 Cocksackievirus A9, Interacts with Major Histocompatibility Complex Class I Molecules
516 Which Mediate Virus Internalization. *JVI*. 2002 Jan 15;76(2):633–43.
- 517 53. Yu D-S, Weng T-H, Hu C-Y, Wu Z-G, Li Y-H, Cheng L-F, et al. Chaperones, Membrane
518 Trafficking and Signal Transduction Proteins Regulate Zaire Ebola Virus trVLPs and Interact
519 With trVLP Elements. *Front Microbiol*. 2018 Nov 12;9:2724.
- 520 54. Amen OM, Sarker SD, Ghildyal R, Arya A. Endoplasmic Reticulum Stress Activates
521 Unfolded Protein Response Signaling and Mediates Inflammation, Obesity, and Cardiac
522 Dysfunction: Therapeutic and Molecular Approach. *Front Pharmacol*. 2019 Sep 10;10:977.
- 523 55. de Ferranti S, Mozaffarian D. The Perfect Storm: Obesity, Adipocyte Dysfunction, and
524 Metabolic Consequences. *Clinical Chemistry*. 2008 Jun 1;54(6):945–55.
- 525 56. Gregor MF, Hotamisligil GS. Thematic review series: Adipocyte Biology. Adipocyte stress:
526 the endoplasmic reticulum and metabolic disease. *J Lipid Res*. 2007 Sep;48(9):1905–14.
- 527 57. Fang L, Kojima K, Zhou L, Crossman DK, Mobley JA, Grams J. Analysis of the Human
528 Proteome in Subcutaneous and Visceral Fat Depots in Diabetic and Non-diabetic Patients with
529 Morbid Obesity. *J Proteomics Bioinform* [Internet]. 2015 [cited 2020 Jun 11];08(06).
530 Available from: [https://www.omicsonline.org/open-access/analysis-of-the-human-proteome-](https://www.omicsonline.org/open-access/analysis-of-the-human-proteome-in-subcutaneous-and-visceral-fat-depotsin-diabetic-and-nondiabetic-patients-with-morbid-obesity-jpb-1000361.php?aid=53283)
531 [in-subcutaneous-and-visceral-fat-depotsin-diabetic-and-nondiabetic-patients-with-morbid-](https://www.omicsonline.org/open-access/analysis-of-the-human-proteome-in-subcutaneous-and-visceral-fat-depotsin-diabetic-and-nondiabetic-patients-with-morbid-obesity-jpb-1000361.php?aid=53283)
532 [obesity-jpb-1000361.php?aid=53283](https://www.omicsonline.org/open-access/analysis-of-the-human-proteome-in-subcutaneous-and-visceral-fat-depotsin-diabetic-and-nondiabetic-patients-with-morbid-obesity-jpb-1000361.php?aid=53283)
- 533 58. Girona J, Rodríguez-Borjabad C, Ibarretxe D, Vallvé J-C, Ferré R, Heras M, et al. The
534 Circulating GRP78/BiP Is a Marker of Metabolic Diseases and Atherosclerosis: Bringing
535 Endoplasmic Reticulum Stress into the Clinical Scenario. *JCM*. 2019 Oct 26;8(11):1793.
- 536 59. Zhu W, Niu X, Wang M, Li Z, Jiang H-K, Li C, et al. Endoplasmic reticulum stress may be
537 involved in insulin resistance and lipid metabolism disorders of the white adipose tissues
538 induced by high-fat diet containing industrial trans-fatty acids. *Diabetes Metab Syndr Obes*.
539 2019;12:1625–38.
- 540 60. Aslani MR, Ghobadi H, Panahpour H, Ahmadi M, Khaksar M, Heidarzadeh M. Modification
541 of lung endoplasmic reticulum genes expression and NF-κB protein levels in obese ovalbumin-
542 sensitized male and female rats. *Life Sciences*. 2020 Apr;247:117446.
- 543 61. Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D. Hypothalamic IKKβ/NF-κB and ER
544 Stress Link Overnutrition to Energy Imbalance and Obesity. *Cell*. 2008 Oct;135(1):61–73.
- 545 62. Boden G, Song W, Duan X, Cheung P, Kresge K, Barrero C, et al. Infusion of Glucose and
546 Lipids at Physiological Rates Causes Acute Endoplasmic Reticulum Stress in Rat Liver.
547 *Obesity*. 2011 Jul;19(7):1366–73.
- 548 63. Sarrazin S, Lamanna WC, Esko JD. Heparan Sulfate Proteoglycans. *Cold Spring Harbor*
549 *Perspectives in Biology*. 2011 Jul 1;3(7):a004952–a004952.

- 550 64. Bermejo-Jambrina M, Eder J, Kaptein TM, Helgers LC, Brouwer PJM, Hamme JL van, et al.
551 SARS-CoV-2 Infection and Transmission Depends on Heparan Sulfates and Is Blocked by
552 Low Molecular Weight Heparins. *bioRxiv*. 2020 Aug 18;2020.08.18.255810.
- 553 65. Hudák A, Szilák L, Letoha T. Contribution of syndecans to the cellular entry of SARS-CoV-2
554 [Internet]. In Review; 2020 Sep [cited 2020 Nov 10]. Available from:
555 <https://www.researchsquare.com/article/rs-70340/v1>
- 556 66. Bellin R, Capila I, Lincecum J, Park PW, Reizes O, Bernfield MR. Unlocking the secrets of
557 syndecans: Transgenic organisms as a potential key. *Glycoconj J*. 2002 May;19(4/5):295–304.
- 558 67. Gordts PLSM, Esko JD. The heparan sulfate proteoglycan grip on hyperlipidemia and
559 atherosclerosis. *Matrix Biology*. 2018 Oct;71–72:262–82.
- 560 68. Landry R, Rioux V, Bensadoun A. Characterization of syndecan-4 expression in 3T3-F442A
561 mouse adipocytes: Link between syndecan-4 induction and cell proliferation. *Cell growth &*
562 *differentiation : the molecular biology journal of the American Association for Cancer*
563 *Research*. 2001 Nov 1;12:497–504.
- 564 69. Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, et al.
565 Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. *Science*. 2020 Oct
566 20;eabd2985.
- 567 70. Ceccarelli S, Nodale C, Vescarelli E, Pontecorvi P, Manganelli V, Casella G, et al. Neuropilin
568 1 Mediates Keratinocyte Growth Factor Signaling in Adipose-Derived Stem Cells: Potential
569 Involvement in Adipogenesis [Internet]. Vol. 2018, *Stem Cells International*. Hindawi; 2018
570 [cited 2020 Nov 6]. p. e1075156. Available from:
571 <https://www.hindawi.com/journals/sci/2018/1075156/>
- 572 71. Magkos F, Mohammed BS, Mittendorfer B. Effect of obesity on the plasma lipoprotein
573 subclass profile in normoglycemic and normolipidemic men and women. *Int J Obes*. 2008
574 Nov;32(11):1655–64.
- 575 72. Miftode R-S, Șerban I-L, Timpau A-S, Miftode I-L, Ion A, Buburuz A-M, et al. Syndecan-1:
576 A Review on Its Role in Heart Failure and Chronic Liver Disease Patients' Assessment.
577 *Cardiology Research and Practice*. 2019 Nov 11;2019:1–7.
- 578 73. Park H-K, Ahima RS. Physiology of leptin: energy homeostasis, neuroendocrine function and
579 metabolism. *Metabolism*. 2015 Jan;64(1):24–34.
- 580 74. Jung CH, Kim M-S. Molecular mechanisms of central leptin resistance in obesity. *Arch Pharm*
581 *Res*. 2013 Feb;36(2):201–7.
- 582 75. Bruno A, Conus S, Schmid I, Simon H-U. Apoptotic Pathways Are Inhibited by Leptin
583 Receptor Activation in Neutrophils. *J Immunol*. 2005 Jun 15;174(12):8090–6.
- 584 76. Caldefie-Chezet F, Poulin A, Vasson M-P. Leptin Regulates Functional Capacities of
585 Polymorphonuclear Neutrophils. *Free Radical Research*. 2003 Jan;37(8):809–14.

- 586 77. Suzukawa M, Nagase H, Ogahara I, Han K, Tashimo H, Shibui A, et al. Leptin Enhances
587 Survival and Induces Migration, Degranulation, and Cytokine Synthesis of Human Basophils.
588 JI. 2011 May 1;186(9):5254–60.
- 589 78. Wong CK, Cheung PF-Y, Lam CWK. Leptin-mediated cytokine release and migration of
590 eosinophils: Implications for immunopathophysiology of allergic inflammation. Eur J
591 Immunol. 2007 Aug;37(8):2337–48.
- 592 79. Wrann CD, Laue T, Hübner L, Kuhlmann S, Jacobs R, Goudeva L, et al. Short-term and long-
593 term leptin exposure differentially affect human natural killer cell immune functions.
594 American Journal of Physiology-Endocrinology and Metabolism. 2012 Jan 1;302(1):E108–16.
- 595 80. Lamas B, Goncalves-Mendes N, Nachat-Kappes R, Rossary A, Caldefie-Chezet F, Vasson M-
596 P, et al. Leptin modulates dose-dependently the metabolic and cytolytic activities of NK-92
597 cells. J Cell Physiol. 2013 Jun;228(6):1202–9.
- 598 81. Agrawal S, Gollapudi S, Su H, Gupta S. Leptin Activates Human B Cells to Secrete TNF- α ,
599 IL-6, and IL-10 via JAK2/STAT3 and p38MAPK/ERK1/2 Signaling Pathway. J Clin
600 Immunol. 2011 Jun;31(3):472–8.
- 601 82. De Rosa V, Procaccini C, Cali G, Pirozzi G, Fontana S, Zappacosta S, et al. A Key Role of
602 Leptin in the Control of Regulatory T Cell Proliferation. Immunity. 2007 Feb;26(2):241–55.
- 603 83. Smigiel KS, Srivastava S, Stolley JM, Campbell DJ. Regulatory T cell homeostasis: steady-
604 state maintenance and modulation during inflammation. Immunol Rev. 2014 May;259(1):40–
605 59.
- 606 84. Gogishvili T, Langenhorst D, Lühder F, Elias F, Elflein K, Dennehy KM, et al. Rapid
607 regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS
608 One. 2009;4(2):e4643.
- 609 85. Matarese G, Procaccini C, De Rosa V, Horvath TL, La Cava A. Regulatory T cells in obesity:
610 the leptin connection. Trends Mol Med. 2010 Jun;16(6):247–56.
- 611 86. Conde J, Scotece M, Abella V, López V, Pino J, Gómez-Reino JJ, et al. An update on leptin as
612 immunomodulator. Expert Review of Clinical Immunology. 2014 Sep;10(9):1165–70.
- 613 87. Howard JK, Flier JS. Attenuation of leptin and insulin signaling by SOCS proteins. Trends in
614 Endocrinology & Metabolism. 2006 Nov;17(9):365–71.
- 615 88. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld Y. The
616 Hyperferritinemic Syndrome: macrophage activation syndrome, Still’s disease, septic shock
617 and catastrophic antiphospholipid syndrome. BMC Med. 2013 Dec;11(1):185.
- 618 89. Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is
619 mainly a leakage product from damaged cells. Metallomics. 2014;6(4):748–73.
- 620 90. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. International Immunology. 2017
621 Nov 1;29(9):401–9.

- 622 91. Pieracci FM, Barie PS. Iron and the risk of infection. *Surg Infect (Larchmt)*. 2005;6 Suppl
623 1:S41-46.
- 624 92. Núñez G, Sakamoto K, Soares MP. Innate Nutritional Immunity. *The Journal of Immunology*.
625 2018 Jul 1;201(1):11–8.
- 626 93. Cavezzi A, Troiani E, Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond
627 inflammation. A narrative review. *Clin Pract [Internet]*. 2020 May 28 [cited 2020 Jun
628 11];10(2). Available from: <https://www.clinicsandpractice.org/index.php/cp/article/view/1271>
- 629 94. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19
630 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med*.
631 2020;46(5):846–8.
- 632 95. Hanif W, Ali O, Shahzad H, Younas M, Iqbal H, Afzal K. Biochemical Markers in COVID-19
633 in Multan. *J Coll Physicians Surg Pak*. 2020 Oct;30(10):1026–9.
- 634 96. Wenzhong L, Hualan L. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures
635 the Porphyrin to Inhibit Human Heme Metabolism. 2020 Mar 30 [cited 2020 Apr 8]; Available
636 from: [https://chemrxiv.org/articles/COVID-](https://chemrxiv.org/articles/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173)
637 [19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_P](https://chemrxiv.org/articles/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173)
638 [orphyrin/11938173](https://chemrxiv.org/articles/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173)
- 639 97. Lippi G, Mattiuzzi C. Hemoglobin value may be decreased in patients with severe coronavirus
640 disease 2019. *Hematology, Transfusion and Cell Therapy*. 2020 Apr;42(2):116–7.
- 641 98. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
642 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China.
643 *JAMA*. 2020 Mar 17;323(11):1061.
- 644 99. Zhou C, Chen Y, Ji Y, He X, Xue D. Increased Serum Levels of Hepcidin and Ferritin Are
645 Associated with Severity of COVID-19. *Med Sci Monit*. 2020 Sep 26;26:e926178.
- 646 100. Lecube A, Hernández C, Pelegrí D, Simó R. Factors accounting for high ferritin levels in
647 obesity. *Int J Obes*. 2008 Nov;32(11):1665–9.
- 648 101. Shoenfeld Y. Corona (COVID-19) time musings: Our involvement in COVID-19
649 pathogenesis, diagnosis, treatment and vaccine planning. *Autoimmunity Reviews*. 2020
650 Apr;102538.
- 651 102. Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. Hobman TC, editor. *PLoS*
652 *Pathog*. 2020 May 22;16(5):e1008536.
- 653 103. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al.
654 Incidence of thrombotic complications in critically ill ICU patients with COVID-19.
655 *Thrombosis Research*. 2020 Apr;S0049384820301201.
- 656 104. Piazza G, Campia U, Hurwitz S, Snyder JE, Rizzo SM, Pfeferman MB, et al. Registry of
657 Arterial and Venous Thromboembolic Complications in Patients With COVID-19. *J Am Coll*
658 *Cardiol*. 2020 03;76(18):2060–72.

105. Wang X, Sahu KK, Cerny J. Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. *J Thromb Thrombolysis* [Internet]. 2020 Oct 15 [cited 2020 Nov 7]; Available from: <https://doi.org/10.1007/s11239-020-02297-z>
106. Ji H-L, Zhao R, Matalon S, Matthay MA. Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. *Physiol Rev*. 2020 01;100(3):1065–75.
107. Madoiwa S. Recent advances in disseminated intravascular coagulation: endothelial cells and fibrinolysis in sepsis-induced DIC. *J Intensive Care* [Internet]. 2015 Feb 19 [cited 2020 Nov 11];3. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940964/>
108. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. *Crit Care*. 2020 18;24(1):360.
109. Schafer K, Konstantinides S. Mechanisms linking leptin to arterial and venous thrombosis: potential pharmacological targets. *Curr Pharm Des*. 2014 Feb 31;20(4):635–40.
110. Buis DTP, Christen T, Smit R a. J, de Mutsert R, Jukema JW, Cannegieter SC, et al. The association between leptin concentration and blood coagulation: Results from the NEO study. *Thromb Res*. 2020;188:44–8.
111. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. *J Am Coll Cardiol*. 2008 Oct 7;52(15):1201–10.
112. Wang H, Luo W, Eitzman D. Leptin in Thrombosis and Atherosclerosis. *CPD*. 2014 Feb 31;20(4):641–5.
113. Scarpace P J. Elevated leptin: consequence or cause of obesity? *Front Biosci*. 2007;12(8–12):3531.
114. Francisco V, Pino J, Campos-Cabaleiro V, Ruiz-Fernández C, Mera A, Gonzalez-Gay MA, et al. Obesity, Fat Mass and Immune System: Role for Leptin. *Front Physiol*. 2018 Jun 1;9:640.
115. Loskutoff David J., Samad Fahumiya. The Adipocyte and Hemostatic Balance in Obesity. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 1998 Jan 1;18(1):1–6.
116. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. *Int J Obes*. 2004 Nov;28(11):1357–64.
117. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. *Nat Med*. 1996 Jul;2(7):800–3.
118. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. *Diabetes*. 1997 May;46(5):860–7.

- 694 119. Darbandi M, Pasdar Y, Moradi S, Mohamed HJJ, Hamzeh B, Salimi Y. Discriminatory
695 Capacity of Anthropometric Indices for Cardiovascular Disease in Adults: A Systematic
696 Review and Meta-Analysis. *Prev Chronic Dis*. 2020 Oct 22;17:E131.
- 697 120. Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on
698 adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity.
699 *Arterioscler Thromb Vasc Biol*. 2000 Apr;20(4):1150–4.
- 700 121. Singh P, Peterson TE, Barber KR, Kuniyoshi FS, Jensen A, Hoffmann M, et al. Leptin
701 upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial
702 cells. *Biochemical and Biophysical Research Communications*. 2010 Jan;392(1):47–52.
- 703 122. Félétou M. Multiple Functions of the Endothelial Cells [Internet]. *The Endothelium: Part 1:*
704 *Multiple Functions of the Endothelial Cells—Focus on Endothelium-Derived Vasoactive*
705 *Mediators*. Morgan & Claypool Life Sciences; 2011 [cited 2020 Nov 12]. Available from:
706 <https://www.ncbi.nlm.nih.gov/books/NBK57148/>
- 707 123. Hasan SS, Fischer A. The Endothelium: An Active Regulator of Lipid and Glucose
708 Homeostasis. *Trends Cell Biol*. 2020 Oct 28;
- 709 124. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes
710 mellitus: molecular insights and therapeutic strategies. *Cardiovasc Diabetol*. 2018
711 31;17(1):121.
- 712 125. Pasquarelli-do-Nascimento G, Braz-de-Melo HA, Faria SS, Santos I de O, Kobinger GP,
713 Magalhães KG. Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May
714 Explain Higher Mortality in COVID-19 Patients With Obesity. *Front Endocrinol (Lausanne)*
715 [Internet]. 2020 Jul 28 [cited 2020 Nov 11];11. Available from:
716 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399077/>
- 717 126. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, Goor H van. Tissue distribution of
718 ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding
719 SARS pathogenesis. *The Journal of Pathology*. 2004;203(2):631–7.
- 720 127. Nägele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. Endothelial dysfunction in
721 COVID-19: Current findings and therapeutic implications. *Atherosclerosis*. 2020 Oct
722 14;314:58–62.
- 723 128. Halder M, Petsophonsakul P, Akbulut AC, Pavlic A, Bohan F, Anderson E, et al. Vitamin K:
724 Double Bonds beyond Coagulation Insights into Differences between Vitamin K1 and K2 in
725 Health and Disease. *Int J Mol Sci*. 2019 Feb 19;20(4):896.
- 726 129. Eden RE, Coviello JM. Vitamin K Deficiency. In: *StatPearls* [Internet]. Treasure Island (FL):
727 StatPearls Publishing; 2020 [cited 2020 Nov 19]. Available from:
728 <http://www.ncbi.nlm.nih.gov/books/NBK536983/>
- 729 130. Proudfoot D, Shanahan CM. Molecular mechanisms mediating vascular calcification: role of
730 matrix Gla protein. *Nephrology (Carlton)*. 2006 Oct;11(5):455–61.

131. Schurgers LJ, Dissel PE, Spronk HM, Soute BA, Dhore CR, Cleutjens JP, et al. Role of vitamin K and vitamin K-dependent proteins in vascular calcification. *Zeitschrift für Phytotherapie*. 2001;90 Suppl 3:57–63.
132. Shea MK, Booth SL, Gundberg CM, Peterson JW, Waddell C, Dawson-Hughes B, et al. Adulthood obesity is positively associated with adipose tissue concentrations of vitamin K and inversely associated with circulating indicators of vitamin K status in men and women. *J Nutr*. 2010 May;140(5):1029–34.
133. Ravera M, Nickolas T, Plebani M, Iervasi G, Aghi A, Khairallah P, et al. Overweight - obesity is associated with decreased vitamin K2 levels in hemodialysis patients. *Clin Chem Lab Med*. 2020 May 8;
134. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. *The American Journal of Clinical Nutrition*. 2000 Sep 1;72(3):690–3.
135. Landrier J-F, Marcotorchino J, Tourniaire F. Lipophilic Micronutrients and Adipose Tissue Biology. *Nutrients*. 2012 Nov 6;4(11):1622–49.
136. Okano T, Shimomura Y, Yamane M, Suhara Y, Kamao M, Sugiura M, et al. Conversion of phylloquinone (Vitamin K1) into menaquinone-4 (Vitamin K2) in mice: two possible routes for menaquinone-4 accumulation in cerebra of mice. *J Biol Chem*. 2008 Apr 25;283(17):11270–9.
137. Al Rajabi A. The Enzymatic Conversion of Phylloquinone to Menaquinone-4. 2011.
138. McCann JC, Ames BN. Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging? *Am J Clin Nutr*. 2009 Oct;90(4):889–907.
139. Dofferhoff ASM, Piscaer I, Schurgers LJ, Walk J, Ouweland JMW van den, Hackeng TM, et al. Reduced vitamin K status as a potentially modifiable prognostic risk factor in COVID-19. 2020 May 29 [cited 2020 May 3]; Available from: <https://www.preprints.org/manuscript/202004.0457/v2>
140. Agarwal P, Wang Y, Holland T, Bennett D, Morris M. Strawberry Consumption Associated with Reduced Alzheimer’s Dementia Risk (FS05-06-19). *Curr Dev Nutr* [Internet]. 2019 Jun 1 [cited 2020 Apr 21];3(Supplement_1). Available from: https://academic.oup.com/cdn/article/3/Supplement_1/nzz052.FS05-06-19/5517975
141. Branca F, Lartey A, Oenema S, Aguayo V, Stordalen GA, Richardson R, et al. Transforming the food system to fight non-communicable diseases. *BMJ* [Internet]. 2019 Jan 28 [cited 2020 Nov 19];364. Available from: <https://www.bmj.com/content/364/bmj.l296>
142. Bruins MJ, Van Dael P, Eggersdorfer M. The Role of Nutrients in Reducing the Risk for Noncommunicable Diseases during Aging. *Nutrients* [Internet]. 2019 Jan 4 [cited 2020 Nov 19];11(1). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356205/>
143. Rauber F, Da Costa Louzada ML, Steele EM, Millett C, Monteiro CA, Levy RB. Ultra-Processed Food Consumption and Chronic Non-Communicable Diseases-Related Dietary Nutrient Profile in the UK (2008–2014). *Nutrients*. 2018 May;10(5):587.

144. Lee I-M, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. *The Lancet*. 2012 Jul 21;380(9838):219–29.
145. Sridhar GR, Sanjana NSN. Sleep, circadian dysrhythmia, obesity and diabetes. *World J Diabetes*. 2016 Nov 15;7(19):515–22.
146. Fricchione GL. The Challenge of Stress-Related Non-Communicable Diseases. *Med Sci Monit Basic Res*. 2018 Jun 15;24:93–5.
147. de Frel DL, Atsma DE, Pijl H, Seidell JC, Leenen PJM, Dik WA, et al. The Impact of Obesity and Lifestyle on the Immune System and Susceptibility to Infections Such as COVID-19. *Front Nutr* [Internet]. 2020 [cited 2020 Nov 26];7. Available from: https://www.frontiersin.org/articles/10.3389/fnut.2020.597600/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Nutrition&id=597600

799 **Tables**

800 **Table 1:** Clinical studies investigating the correlation between obesity and disease severity in COVID-
801 19 patients.

Reference	Study design	Predictor	Outcome	Effect
Battisti et al., 2020 [28]	Cohort study (n= 441)	VAT/SAT ratio	ICU admission	VAT/SAT is associated with increased risk of ICU admission
Chandarana et al., 2020 [26]	Retrospective study (n=51)	VAT, SAT, TAT, VAT/TAT and BMI	Hospitalization	Higher VAT and VAT/TAT in hospitalized patients.
Frank et al., 2020 [22]	Retrospective cohort study (n=305)	BMI categories: BMI < 25, BMI ≥ 25 to < 30, BMI ≥ 30 to < 35, and BMI ≥ 35	Intubation, death	BMI ≥ 30 was associated with an increased risk of intubation or death
Kalligeros et al., 2020 [29]	Retrospective cohort study (n=103)	BMI categories: BMI <25, BMI 25-29.9, BMI 30-34.9, BMI ≥35	ICU admission, IMV	Severe obesity (BMI ≥ 35) was positively associated with ICU admission. Obesity (BMI 30-34.9) and severe obesity were positively associated with the use of IMV.
Kim et al., 2020 [23]	Retrospective cohort study (n=10,861)	BMI categories: underweight (BMI < 18.5), normal (BMI 18.5-24.9), overweight (BMI 25-29.9), obesity class I (BMI 30-34.9), obesity class II (BMI 35-39.9), and obesity class III (BMI ≥ 40).	IMV, death	Categories: overweight, obesity class I, II and III were associated with increased risk of requiring IMV. Underweight and obesity classes II and III were associated with increased risk of death.
Nakeshbandi et al., 2020 [21]	Retrospective cohort study (n=504)	BMI categories: normal (BMI 18.5- 24.99), overweight (BMI 25-29.99), and obese (BMI ≥ 30).	Mortality, intubation	Patients with overweight and obesity were at increased risk for mortality and intubation compared to those with normal BMI.
Palaiodimos et al., 2020 [24]	Retrospective cohort study (n=200)	BMI categories: BMI < 25, BMI 25-34, BMI ≥ 35	In-hospital mortality, Worse in-hospital outcomes	Severe obesity (BMI ≥35) was associated with higher in-hospital mortality and worse in-hospital outcomes.
Rao et al., 2020 [25]	Retrospective cohort study (n=240)	BMI (overweight, BMI > 28)	In-hospital death, COVID-19 severity	Being overweight was related to COVID-19 severity but not to in-hospital death.
Simonnet et al., 2020 [30]	Retrospective cohort study (n=124)	BMI categories: lean (BMI 18.5 to < 25), overweight (25 to < 30), moderate obesity (BMI 30 to < 35) and severe obesity (BMI ≥ 35)	Need for IMV	Increased BMI categories were associated with a greater need for IMV.
Zhu et al., 2020 [27]	Retrospective cohort study (n=489,769)	BMI, categories: normal weight (BMI, 18.5–24.9), overweight (25.0–29.9), and obese (≥30); waist circumference and waist-to-hip ratio	Hospitalization with 'severe COVID-19'	BMI, waist circumference and waist-to-hip ratio were positively associated with the risk of severe COVID-19.

802 **Abbreviations:** VAT=visceral adipose tissue; SAT=subcutaneous adipose tissue; TAT=total adipose tissue;
803 BMI=body mass index (kg/m²); IMV=invasive mechanical ventilation; ICU=intensive care unit.

804

805

806 **Figures**

807

808 **Figure 1**

809

810 **Figure 1:** Schematic representation of different mechanisms through which obesity increases COVID-
 811 19 disease severity and the risk for complications. Obesity is characterized by large hypoxic adipocytes
 812 infiltrated with immune cells and M1 macrophages leading to a chronic inflammatory state,
 813 hypercoagulability and hyperferritinemia. ACE2 produced by adipocytes may serve as viral entry into
 814 the adipose tissue possibly functioning as a reservoir for the virus. The constant tissue expansion and
 815 tissue remodeling accompanying obesity in concert with high cell stress can upregulate the expression
 816 of other potential SARS-CoV-2 receptors, such as GRP78, HSPG and NRP-1 in the adipose tissue and
 817 other organs. Obesity-associated endothelial dysfunction, enhanced production of PAI-1, and vitamin
 818 K deficiency all increase the risk of developing COVID-19 associated coagulopathy.

819